The Importance of Carfilzumib in the Treatment of Myeloma

I think that it really comes down to risk benefit ratio. And we saw in the E-Cog trial that randomized VRD versus KRD, there was no difference in progression for survival. In a high risk population, I think that all bets are off. Reducing the dose of portesumib may be more likely to occur from twice a week to once a week,. You don't have to do that quite as often with carfilzumib. When you're talking about quad versus quad, I'm not so sure that there really, again, remains that big difference between Dara VRD and Dara KRD.